Global Acute Kidney Injury Treatment Market: Regional Analysis; Key Segmentation and Scope; Industry Opportunities and Challenges; Market Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, Key Indicators for Demand, Key Indicators for Price; Value Chain Analysis; Industry Events and Developments; Competitive Landscape, 2022-2027

Acute Kidney Injury Treatment Industry Report by Regional Category Spend, Price Analysis, Key Demand, and Price Indicators, and Best Buying Practices

The global Acute Kidney Injury Treatment market reached a value of about USD 39.26 billion in 2021. The industry is projected to grow at a CAGR of around 6.1% in the forecast period of 2022-2027 to reach a value of about USD 56.00 billion by 2027.

The global Acute Kidney Injury Treatment industry report gives a comprehensive analysis of the industry, including key segments, trends, drivers, restraints, the competitive landscape, and other essential market aspects. The rising acute kidney injury condition cases are driving the demand for the treatment market. North America is the highest category spender by region, driving the need for the Acute Kidney Injury Treatment industry.

Industry Definition and Segmentation

Acute kidney injury (AKI), which includes both injury (structural damage) and impairment, is characterised as a sudden (within hours) decline in kidney function (loss of operation). Rarely does a condition have single, identifiable pathogenesis. The kidneys may abruptly cease functioning if one has acute kidney injury. It might result in a slight decline in kidney function to total renal failure. AKI makes it difficult for your kidneys to maintain the proper fluid balance in the body and ends in a buildup of waste products in the blood. The Acute Kidney Injury Treatment industry report comprises segments by Type (Prerenal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injury, Postrenal Acute Kidney Injury, Others), Treatment (Dialysis, Supportive Care), End-Use (Hospitals, Ambulatory Surgical Centres, Others) and Region (North America, Europe, Asia Pacific, the Middle East, and Africa, and South America).

North American Region is Driving the Growth of the Industry

North America holds a significant share in the industry due to the growing use of cutting-edge technology in the area. The treatment market in the region is predicted to have considerable growth due to the robust continuing clinical pipeline and the developments in technology, which further enable more efficient products.

The industry is being driven by an ageing population and an increase in acute kidney injury cases. Furthermore, the growing number of dialysis facilities, among other treatment modalities, is further boosting the market demand. In addition, the danger of kidney damage has grown due to the rising elderly population, poor nutrition, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic illnesses are other causes contributing to the market's expansion.

Best Procurement Practices

The global Acute Kidney Injury Treatment industry report by Procurement Resource gives an in-depth analysis of the best buying practices followed by major global Acute Kidney Injury Treatment regions across the globe, such as engagement models, contract terms, and buyer and supplier negotiation levers, among others.

Category Management Studies

The treatment depends on the condition of the patient. The doctor can advise intravenous (IV) fluids if a deficiency in fluids in the blood is the root cause of acute renal failure. In some situations, swelling in the arms and legs occurs, and drugs are advised to help the body flush out additional fluids. The doctor may advise calcium, glucose, or sodium polystyrene sulfonate if the kidneys aren't effectively removing potassium from your blood to avoid the buildup of excessive potassium levels in the blood. Also, Temporary hemodialysis, or dialysis, may be performed to assist in eliminating toxins and extra fluids from your body while your kidneys repair if toxins build up in your blood. An artificial kidney removes waste from the blood as it is pumped out of the body.

Improvements in Diagnostic Technologies, Further Driving the Acute Kidney Injury Treatment Market

The improvements are aiding the industry in diagnostic technologies and increasing the number of acute renal injuries. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system would boost market revenue. The critical renal injury treatment market in the Asia Pacific is also anticipated to grow due to government research and development activities and programmes.

However, the high cost of dialysis therapy and the low patient compliance to a long-term treatment plan will likely hamper the market growth.

The regional markets for the industry can be divided into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific.

Key Industry Players Mentioned in the Acute Kidney Injury Treatment Industry Report

• Angion
• AM-Pharma B.V.
• Baxter International, Inc.
• Fresenius Medical Care Holdings, Inc.
• Asahi Kasei Medical Co., Ltd.

Market Landscape

Major companies are investing in creating innovative therapies, which are anticipated to provide lucrative prospects for market participants to expand. Key players are concentrating on adopting growth tactics, including product launch, regulatory approval, and research and development. Several other firms are developing diagnostic technologies to simplify their product offerings in growing markets with various product portfolios. To provide patients with cutting-edge care, industry leaders are concentrating on creating automated, portable, and technologically sophisticated dialysis equipment. They are also incorporating advanced technology like artificial intelligence and the internet of things (IoT) to diversify their product offering.

Key Initiatives by Companies

• In April 2021, Vifor Pharma, a large pharmaceutical company, and Angion Biomedica Corp, a late-stage biopharmaceutical company, announced that enrollment for Angion's AKI-002-15 study, a Phase II trial of ANG-3777 in patients at risk of cardiac surgery-related acute kidney injury, had been completed (CSA-AKI).
• Abionyxx reported in June 2021 that the first patient had been enrolled in its Phase-2a clinical research using CER-001 to treat septic patients with a high risk of acute kidney damage.